Figure 5

Inhibitory effect of KIN-841 on the production of angiogenic factor in 3LL cells under hypoxia. (A) Effect of 3LL cell-CM treated with KIN-841 at the various concentrations indicated under normoxia or hypoxia on [³H]thymidine incorporation in BPAE cells. ^aP<0.01 vs normoxia controls; ^bP<0.01 vs hypoxia controls. (B) Effects of KIN-841 and anti-VEGF antibody on stimulation of [³H]thymidine incorporation in BPAE cells by 3LL cell-CM incubated under normoxia or hypoxia. ^aP<0.05 vs normoxia controls; ^bP<0.05 vs normoxia controls; ^cP<0.01 vs hypoxia controls. (C) VEGF concentration in 3LL cell-CM treated with KIN-841 at the various concentrations indicated under normoxia or hypoxia. ^aP<0.05 vs normoxia controls; ^bP<0.05 vs hypoxia controls; ^cP<0.01 vs hypoxia controls.